Simcyp Citations RSS Feed

Zientek M & Dalvie D

Wed, 21 Mar 2012 00:00:00 GMT

Use of a multistaged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug-drug interaction potential. Drug Metabolism & Disposition 40, 467-473, March 2012

Sinha VK et al.

Wed, 21 Mar 2012 00:00:00 GMT

From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharmaceutics & Drug Disposition 33, 111-121, March 2012

Tonnelier A et al.

Wed, 21 Mar 2012 00:00:00 GMT

Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Archives of Toxicology 86, 393-403, March 2012

Chen Y et al.

Thu, 1 Mar 2012 00:00:00 GMT

Application of IVIVE and PBPK modelling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharmaceutics & Drug Disposition 33, 85-98, March 2012

Shaffer CL et al.

Thu, 1 Mar 2012 00:00:00 GMT

Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharmaceutics & Drug Disposition 33, 72-84, March 2012

Chappell JC et al.

Thu, 1 Mar 2012 00:00:00 GMT

Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study. European Journal of Clinical Pharmacology 68, 239-247, March 2012

Bouzom F et al.

Thu, 1 Mar 2012 00:00:00 GMT

Physiologically Based PharmacoKinetic (PBPK) modelling tools: how to fit with our needs? Biopharmaceutics & Drug Disposition 33, 55-71, March 2012

Pithavala, YK et al.

Wed, 1 Feb 2012 00:00:00 GMT

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Investigational New Drugs 30, 273-281, February 2012

Plowchalk DR & Rowland-Yeo K

Thu, 19 Jan 2012 00:00:00 GMT

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. European Journal of Clinical Pharmacology E-Publication Ahead Of Print, 2012

Harrison A et al.

Sun, 1 Jan 2012 00:00:00 GMT

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica 42, 57-74, January 2012

Boulenc X et al.

Sun, 1 Jan 2012 00:00:00 GMT

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metabolism & Disposition 40, 187-197, January 2012

Jayaraman R et al.

Tue, 20 Dec 2011 00:00:00 GMT

Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metabolism & Disposition 39, 2219-2232, December 2011

Tortorici MA et al.

Thu, 1 Dec 2011 00:00:00 GMT

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Investigational New Drugs 29, 1370-1380, December 2011

Friedman EJ et al.

Tue, 1 Nov 2011 00:00:00 GMT

Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? Journal of Clinical Pharmacology 51, 1561-1570, November 2011

Damle B

Tue, 1 Nov 2011 00:00:00 GMT

Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrobial Agents & Chemotherapy 55, 5172-7177, November 2011

Chen Y et al.

Tue, 1 Nov 2011 00:00:00 GMT

Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocyte and assessment of human drug-drug interactions. Drug Metabolism and Disposition 39, 2085-2092, November 2011

Berry LM et al.

Tue, 1 Nov 2011 00:00:00 GMT

Species differences in distribution and prediction of human Vss from preclinical data. Drug Metabolism and Disposition 39, 2103-2116, November 2011

Ogilvie BW et al.

Tue, 1 Nov 2011 00:00:00 GMT

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabolism & Disposition 39, 2020-2033, November 2011

Jornil J et al.

Sun, 9 Oct 2011 00:00:00 GMT

Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. European Journal of Pharmaceutical Sciences 44, 265-272, October 2011

Malhotra B et al.

Wed, 10 Aug 2011 00:00:00 GMT

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. British Journal of Clinical Pharmacology 72 , 263-269, August 2011

Wattanachai N et al.

Mon, 1 Aug 2011 00:00:00 GMT

In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6a-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. European Journal of Clinical Pharmacology 67, 815-824, August 2011

Xu Y et al.

Fri, 1 Jul 2011 00:00:00 GMT

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metabolism & Disposition 39, 1139-1148, July 2011

Miyagi SJ & Collier AC

Sun, 1 May 2011 00:00:00 GMT

The development of UGT1A1 and 1A6 in the pediatric liver. Drug Metabolism & Disposition 39, 912-919, May 2011

Sinha VK et al.

Sun, 1 May 2011 00:00:00 GMT

Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry. Clinical Pharmacokinetics 50, 307-318, May 2011

Rekic D et al.

Thu, 7 Apr 2011 00:00:00 GMT

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. British Journal of Clinical Pharmacology 71, 536-543, April 2011

Judson RS et al.

Fri, 1 Apr 2011 00:00:00 GMT

Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem Res Toxicol 24, 451-462, April 2011

Chen Y et al.

Tue, 15 Mar 2011 00:00:00 GMT

Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metabolism and Disposition 39, 373-382, March 2011

Nettleton DO & Einolf HJ

Wed, 16 Feb 2011 00:00:00 GMT

Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development. Current Topics in Medicinal Chemistry 11, 382-403, February 2011

Gandelman K et al.

Tue, 1 Feb 2011 00:00:00 GMT

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. Journal of Clinical Pharmacology 51, 229-236, February 2011

Idkaidek N & Arafat T

Wed, 12 Jan 2011 00:00:00 GMT

Effect of microgravity on the pharmacokinetics of ibuprofen in humans. J Clin Pharmacol 51, 1685-1689, December 2011

Guest EJ et al.

Mon, 3 Jan 2011 00:00:00 GMT

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. British Journal of Clinical Pharmacology 71, 72-87, January 2011

Motta P et al.

Wed, 1 Dec 2010 00:00:00 GMT

Casopitant: in-vitro data and Simcyp^TM simulation to predict in-vivo metabolic interactions involving Cytochrome P450 3A4. Drug Metabolism & Disposition 39, 363-372, December 2010

Zhao P et al.

Wed, 1 Dec 2010 00:00:00 GMT

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clinical Pharmacology & Therapeutics 89, 259-267, December 2010

Guest EJ et al.

Wed, 1 Dec 2010 00:00:00 GMT

Critique of the two-fold measure of prediction success for ratios:
application for the assessment of drug-drug interactions. Drug Metabolism & Disposition 39, 170-173, December 2010

Jin JY et al.

Mon, 22 Nov 2010 00:00:00 GMT

Use of the Simcyp Population-Based ADME Simulator in early drug development: examples. PSWC / AAPS Meeting New Orleans, USA, 13th-19th November 2010

Sinha VK et al.

Mon, 22 Nov 2010 00:00:00 GMT

Prediction of oral absorption and drug drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling. PSWC / AAPS Meeting New Orleans, USA, 13th-19th November 2010

Venkatakrishnan K

Mon, 1 Nov 2010 00:00:00 GMT

A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs. Clinical Pharmacokinetics 49, 703-727, November 2010

Rotroff DM et al.

Fri, 1 Oct 2010 00:00:00 GMT

Incorporating human dosimetry and exposure into high-throughput In vitro toxicity screening. Toxicological Sciences 117, 348-358, October 2010

Shaffer CL et al.

Mon, 13 Sep 2010 00:00:00 GMT

Using Simcyp® to project human oral pharmacokinetic variability in lead development to mitigate mechanism-based adverse events in the clinic. 9th International ISSX Meeting Istanbul, Turkey, September 4th-8th 2010

Wang YH

Thu, 1 Jul 2010 00:00:00 GMT

Confidence assessment of predicting clinical drug interactions of mechanism-based CYP3A inhibitors using Simcyp time-based approach and a static mathematic model. Drug Metabolism & Disposition 38, 1094-1104, July 2010

Foti RS et al.

Tue, 1 Jun 2010 00:00:00 GMT

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metabolism and Disposition 38, 981-987, June 2010

Jornil J et al.

Mon, 1 Mar 2010 00:00:00 GMT

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metabolism & Disposition 38, 376-385, March 2010

Polasek TM et al.

Mon, 1 Mar 2010 00:00:00 GMT

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. European Journal of Clinical Pharmacology 66, 275-283, March 2010

Berry LM et al.

Fri, 1 Jan 2010 00:00:00 GMT

Prediction of V(ss) from in vitro tissue binding studies. Drug Metabolism & Disposition 38, 115-121, January 2010

Xu L et al.

Tue, 1 Dec 2009 00:00:00 GMT

Prediction of human drug and drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metabolism & Disposition 37, 2330-2339, December 2009

Caldwell GW et al.

Mon, 23 Nov 2009 00:00:00 GMT

ADME optimization and toxicity assessment in early- and late-phase drug discovery. Current Topics in Medicinal Chemistry 9, 965-980, 2009

Wong H et al.

Sun, 1 Nov 2009 00:00:00 GMT

Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 39, 850-861, November 2009

De Groot MJ et al.

Fri, 9 Oct 2009 00:00:00 GMT

Understanding CYP2D6 interactions. Drug Discovery Today 14, 964-972, October 2009

Espié P et al.

Fri, 9 Oct 2009 00:00:00 GMT

Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 41, 391-407, 2009

Polasek TM et al.

Fri, 9 Oct 2009 00:00:00 GMT

Assessment of inter-individual variability in predicted phenytoin clearance. European Journal of Clinical Pharmacology 65, 1203-1210, December 2009

Foti RS et al.

Tue, 1 Sep 2009 00:00:00 GMT

In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metabolism & Disposition 37, 1848-1855, September 2009

Gibson CR et al.

Tue, 18 Aug 2009 00:00:00 GMT

Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 39, 637-648, September 2009

Fahmi OA et al.

Tue, 18 Aug 2009 00:00:00 GMT

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metabolism & Disposition 37, 1658-1666, August 2009

Chu V et al.

Fri, 10 Jul 2009 00:00:00 GMT

In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabolism & Disposition 37, 1339-1354, July 2009

Grimm SW et al.

Fri, 10 Jul 2009 00:00:00 GMT

The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America (PhRMA). Drug Metabolism & Disposition 37, 1355-1370, July 2009

Hyland R et al.

Mon, 20 Apr 2009 00:00:00 GMT

In vitro and in vivo glucuronidation of midazolam in humans. British Journal of Clinical Pharmacology 67, 445-454, April 2009

Emoto C et al.

Mon, 23 Mar 2009 00:00:00 GMT

Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 39, 227-235, March 2009

Thelingwani RS et al.

Thu, 19 Mar 2009 00:00:00 GMT

In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metabolism & Disposition 37, 1286-1294, June 2009

Summerfield S & Jeffrey P

Thu, 19 Mar 2009 00:00:00 GMT

Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opinion on Drug Discovery 4, 207-218, 2009

Badwan A et al.

Sun, 1 Mar 2009 00:00:00 GMT

Enhancement of oral bioavailability of insulin in humans. Neuro Endocrinology Letters 30, 74-78, March 2009

Zhao P et al.

Fri, 27 Feb 2009 00:00:00 GMT

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. Journal of Clinical Pharmacology 49, 351-359, March 2009

Grime KH et al.

Sun, 15 Feb 2009 00:00:00 GMT

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36, 175-191, February 2009

Bouzom F & Walther B

Mon, 1 Dec 2008 00:00:00 GMT

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundamentals of Clinical Pharmacology 22, 579-587, December 2008

Hyland R et al.

Wed, 1 Oct 2008 00:00:00 GMT

Maraviroc: in vitro assessment of drug-drug interaction potential. British Journal of Clinical Pharmacology 66, 498-507, October 2008

Westerhoff HV et al.

Tue, 2 Sep 2008 00:00:00 GMT

Integrating systems approaches into pharmaceutical sciences. European Journal of Pharmaceutical Sciences 35, 1-4, September 2008

Karalis V et al.

Fri, 1 Aug 2008 00:00:00 GMT

Bioavailability and bioequivalence: focus on physiological factors and variability. Pharmaceutical Research 25, 1956-1962, August 2008

McGinnity DF et al.

Sun, 1 Jun 2008 00:00:00 GMT

Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metabolism & Disposition 36, 1126-1134, June 2008

Fowler S & Zhang H

Sun, 1 Jun 2008 00:00:00 GMT

In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. The AAPS Journal 10, 410-424, June 2008

Youdim KA et al.

Thu, 1 May 2008 00:00:00 GMT

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions: predictions of compounds as objects of interaction. British Journal of Clinical Pharmacology 65, 680-692, May 2008

Foti RS et al.

Sat, 1 Mar 2008 00:00:00 GMT

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 38, 264-280, March 2008

Dong JQ et al.

Sat, 1 Mar 2008 00:00:00 GMT

Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration. Current Computer-Aided Drug Design 4, 54-66, March 2008

Rakhit A et al.

Tue, 1 Jan 2008 00:00:00 GMT

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Simcyp) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology 64, 31-41, January 2008

De Buck SS & Mackie CE

Sat, 1 Dec 2007 00:00:00 GMT

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opinion on Drug Metabolism & Toxicology 3, 865-878, December 2007

Einolf HJ

Sun, 7 Oct 2007 00:00:00 GMT

Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37, 1257-1294, October-November 2007

Riley RJ et al.

Thu, 1 Feb 2007 00:00:00 GMT

Time-dependent CYP inhibition. Expert Opinion on Drug Metabolism & Toxicology 3, 51-66, February 2007

Ekins S et al.

Fri, 1 Apr 2005 00:00:00 GMT

Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends in Pharmacological Science 26, 202-209, April 2005

Wishart DS

Tue, 1 Mar 2005 00:00:00 GMT

Bioinformatics in drug development and assessment. Drug Metabolism Reviews 37, 279-310, 2005